Cancer spinout to take forward novel blood cancer immunotherapy

31 March 2023

A new oncology-focused spinout will be launched by Citius Pharmaceuticals (Nasdaq: CTXR), with the goal of developing the immuno-oncology asset I/ONTAK.

The New Jersey, USA-based company is focused on developing and commercializing first-in-class critical care products.

A designated orphan drug candidate in the USA, I/ONTAK - also known as E7777 - is being developed in a rare form of non-Hodgkin lymphoma, cutaneous T-cell lymphoma (CTCL).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK